<DOC>
	<DOC>NCT02750514</DOC>
	<brief_summary>The purpose of this study is to determine whether nivolumab in combination with other therapies is more effective than nivolumab alone in people with advanced lung cancer.</brief_summary>
	<brief_title>A Study to Test Combination Treatments in People With Advanced Non-Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<mesh_term>Dasatinib</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>For more information regarding BristolMyers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com Advanced Non Small Cell Lung Cancer (NSCLC) Eastern Cooperative Oncology Group (ECOG) Performance status of â‰¤ 1 Life expectancy of at least 3 months from most recent chemotherapy or immunotherapy treatment Must have at least 1 lesion with measurable disease Subjects with certain mutations that have not been treated with a targeted therapy prior to enrollment Subjects who need daily oxygen therapy People with autoimmune disease Other protocol defined inclusion/exclusion criteria could apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>